Advanced Solutions Life Sciences, LLC

Advanced Solutions Life Sciences, LLC is a for-profit limited liability company headquartered in Louisville, Kentucky, that specializes in advanced 3D bioprinting and vascularization technologies for the fabrication of human tissues and organs. The company, registered in SAM.gov since March 4, 2016, has established itself as a key federal supplier of specialized bioprinting equipment and related services, with a primary focus on supporting research and development efforts across multiple federal agencies in the healthcare and medical innovation sectors.

Through its federal contract awards, Advanced Solutions Life Sciences has delivered a diverse portfolio of bioprinting systems and ancillary equipment to multiple federal agencies without set-aside designations, indicating open competition. The company has provided BioAssemblyBot series 3D bioprinters (Models 200, 400, and 500) to the Department of Veterans Affairs across multiple Veterans Integrated Service Networks, the Department of the Navy's Bureau of Medicine and Surgery, the U.S. Environmental Protection Agency's Office of Research and Development, the National Institutes of Health's National Cancer Institute, and the Uniformed Services University of the Health Sciences. Notably, Advanced Solutions Life Sciences secured a substantial $1,655,493.40 firm fixed-price purchase order from the VA Strategic Acquisition Center Frederick for a multi-axis robot designed for 3D printing of silicones and biologics to facilitate tissue structure fabrication. Additional contract deliverables have included BioStorageBot incubators with accessories, on-site training and installation services, and biomedical fabrication support. The company's largest ongoing commitment is a $390,401.00 definitive contract awarded by the Navy's Bureau of Medicine and Surgery on August 19, 2024, for procurement of a BioAssemblyBot 500 Series system, with performance extending through November 10, 2028, representing the Navy's recognition of Advanced Solutions Life Sciences as a sole-source provider capable of meeting specialized bioprinting requirements.

Advanced Solutions Life Sciences has participated in federal grant sub-awards focused on advancing tissue engineering and bioprinting research methodologies. The company received two separate federal grant sub-award notices dated August 30, 2022, for work on "VOC-Based, In-Line, Rapid Sensing of Tissue Fabrication," and two additional sub-award notices dated February 3, 2022, for "Generating a Vascularized Human Pediatric Heart." These grant sub-awards demonstrate the company's involvement in cutting-edge research initiatives aimed at developing sensing capabilities for tissue fabrication processes and advancing the creation of complex vascularized organ structures, particularly in pediatric applications. While specific grant program details and funding agency designations for these sub-awards are not explicitly detailed in the available documentation, the nature of these awards indicates Advanced Solutions Life Sciences' participation in research initiatives likely funded through the National Institutes of Health or related federal biomedical research programs, positioning the company as a technical partner in advancing regenerative medicine and tissue engineering capabilities for the federal government.